US2995560A - Acetates of 3-piperidinol - Google Patents
Acetates of 3-piperidinol Download PDFInfo
- Publication number
- US2995560A US2995560A US839288A US83928859A US2995560A US 2995560 A US2995560 A US 2995560A US 839288 A US839288 A US 839288A US 83928859 A US83928859 A US 83928859A US 2995560 A US2995560 A US 2995560A
- Authority
- US
- United States
- Prior art keywords
- ethyl
- ether
- piperidyl
- content
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 title description 4
- 150000001242 acetic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 70
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- -1 cyclic aminoalcohols Chemical class 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 13
- 229910052753 mercury Inorganic materials 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- ZNPSUOAGONLMLK-UHFFFAOYSA-N 1-ethylpiperidin-3-ol Chemical compound CCN1CCCC(O)C1 ZNPSUOAGONLMLK-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 11
- 239000012458 free base Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000005392 Spasm Diseases 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- XFEJOGHZSITRAL-UHFFFAOYSA-N 3-chloro-1-ethylpiperidine Chemical compound CCN1CCCC(Cl)C1 XFEJOGHZSITRAL-UHFFFAOYSA-N 0.000 description 5
- 230000002921 anti-spasmodic effect Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 3
- 229940087675 benzilic acid Drugs 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- PYHXGXCGESYPCW-UHFFFAOYSA-N diphenylacetic acid Chemical group C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 3
- 150000002168 ethanoic acid esters Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- DKXADVGOZWGRNK-UHFFFAOYSA-N (1-ethylpiperidin-3-yl) 2-hydroxy-2,2-diphenylacetate;hydrochloride Chemical compound Cl.C1N(CC)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 DKXADVGOZWGRNK-UHFFFAOYSA-N 0.000 description 2
- UKANCZCEGQDKGF-UHFFFAOYSA-N 1-methylpiperidin-3-ol Chemical compound CN1CCCC(O)C1 UKANCZCEGQDKGF-UHFFFAOYSA-N 0.000 description 2
- AAJLPPDFIRPBDA-UHFFFAOYSA-N 2-cyclohexyl-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1CCCCC1 AAJLPPDFIRPBDA-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- YZVDEVQOPPKHFU-UHFFFAOYSA-N 9h-fluorene-9-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)C3=CC=CC=C3C2=C1 YZVDEVQOPPKHFU-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- VSBFNCXKYIEYIS-UHFFFAOYSA-N Xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940102396 methyl bromide Drugs 0.000 description 2
- 230000003170 musculotropic effect Effects 0.000 description 2
- 230000002276 neurotropic effect Effects 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JXHHIAPAEUSUPW-UHFFFAOYSA-N 2-cyclohexyl-2-phenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1CCCCC1 JXHHIAPAEUSUPW-UHFFFAOYSA-N 0.000 description 1
- OSGGRLYAWNSAGG-UHFFFAOYSA-N 2-cyclopentyl-2-phenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1CCCC1 OSGGRLYAWNSAGG-UHFFFAOYSA-N 0.000 description 1
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100168115 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-6 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RBGWCEWDAHDPEH-UHFFFAOYSA-N Piperidolate hydrochloride Chemical compound Cl.C1N(CC)CCCC1OC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 RBGWCEWDAHDPEH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- BCQMRZRAWHNSBF-UHFFFAOYSA-N desmethylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1 BCQMRZRAWHNSBF-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OJYOTLHNSMYONM-UHFFFAOYSA-N n-ethyl-3-piperidyl benzilate Chemical compound C1N(CC)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 OJYOTLHNSMYONM-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000004010 onium ions Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
Definitions
- This invention relates to an ester of cyclic aminoalcohols and particularly to an acetic ester of N-ethyl-3- piperidinol and the salts thereof.
- the reduction or smooth muscle spasm, whether of musculotropic or neurotropic, by atropine, and by various synthetic compounds related in structure to atropine or papaverine, is well known. While many of these compounds will eifectively abolish one or the other type of spasm, they are not capable of relieving both types of muscle spasm. Furthermore, the action of the known compounds is usually accompanied by undesirable side eiieots such as dilatation of the pupil of the eye, dryness of the mouth, large increase in rate of heart beat, hypotension, nausea, and vomiting.
- esters of N-alkyl-4-piperidinol have been found to be active anti-spasmodics or spasmolytics, but such esters have never been put into use. It is well known that changes in the positions of certain substituents on the piperidine ring may produce profound differences in the physiological activity and effects of such compounds, which differences are not predictable.
- N-methyl-4- phenyl-4-propionoXy-piperidine is a potent analgesic
- the corresponding N-methyl-Z-phenyl-Z-propionoxy-pipen'dine has only slight analgesic properties
- beta-4-methyl-piperidine-ethyl benzoate has considerable anesthetic action while the 2- and 3-methyl derivatives have no such action.
- substituted acetic acid esters of N- ethyl-3-piperidinol are effective as an anti-spasmodic in both musculotropic and neurotropic spasms and have longer duration of action with fewer undesirable side eflects than various other anti-spasmodics now used.
- an object of the present invention to provide a compound for pharmaceutical purposes and having the effect of reducing either involuntary muscle or nervous spasm.
- Another object of the invention is to provide a compound having an anti-spasmodic effect in humans, which compound is long lasting in action and which will have only a few undesirable side reactions of minor importance.
- a further object of the invention is to provide a series of substituted acetic acid esters of N-ethyl-3-piperidinol having longer activity and side reactions both less in number and of lower intensity than other compounds now in use for reducing spasm of human muscle or nerves.
- the present invention includes the substituted acetic acid esters of N-alkyl-3-piperidinol and the salts thereof and the preparation of such compounds by States atent O the use of simple equipment and procedures. pounds conform to the type formula:
- R is an alkyl radical
- R2 is H or OH where: R, and R are lower alkyl radicals and X is an inorganic radical.
- N-ethyl-B-piperidyl-diphenylacetate hydrochloride was formed by heating equimolecular amounts of N-ethyl-3- piperidinol and diphenylacetyl chloride in the presence of a solvent for the reactants.
- the hydrochloride salt was precipitated and is readily purified by recrystallization from a suitable solvent.
- the free base N-ethyl-S-piperidyl diphenylacetate was obtained as an oily material, by treating thesaid hydrochloride with sodium hydroxide.
- N- ethyl-3-piperidyl-diphenylacetate-methiodide was formed by treating free N-cthyl-3-piperidyl-diphenylacetate in an ether solution with methyl iodide.
- N-methyl-3-piperidyl-diphenylacetate and its hydrochloride salt differ from the preceding compositions by the substitution of a methyl group on the N of the piperidine ring.
- the base was made by refluxing N- methyl-3-hydroxy-piperidine with diphenylacetyl chloride and pyridine. The refluxed material is neutralized and extracted with ether. The extract was dried and the ether removed, and the base recovered by vacuum distillation. A solution of the base in ethereal hydrochloric acid precipitated the hydrochloride in crystalline form.
- N-ethyl-3-piperidyl-phenylcyclohexylacetate and its hydrochloride and other salts differ from the above compounds by reduction of one of the rings of the diphenyl acetic acid moiety to a cyclohexyl ring. Such reduction was carried out in glacial acetic acid with platinum oxide to give phenylcyclohexylacetic acid. The acid was treated with thionyl chloride to obtain the chloride of the acid which was then reacted with pyridine and N-ethyl-3- piperidinol. The resulting compound was neutralized, extracted with ether and dried. After removing the ether, vacuum distillation gave the desired base.
- the hydrochloride of the above base was formed by dissolving the base in ether and adding ethereal hydrochloric acid.
- the methobromide of the above base was formed by dissolvingthe above base in ethyl alcohol and adding methylbromide which is allowed to stand until the reaction is completed. The mixture was then concentrated and the volatiles were removed.
- N ethyl 3 piperidyl benzilate hydrochloride differs from the preceding compounds by the addition of a hydroxy group to the diphenylacetic acid moiety.
- N- ethyl-3-chloro-piperidine, benzilic acid and isopropanol were refluxed together, filtered and concentrated in vacuo. The concentrate was dissolved acidified and the unreacted acid was removed with ether. After neutralizing the aqueous layer of the mixture, the product was extracted with ether and the solution was dried. The ether was removed and the free base was obtained by vacuum distillation. The hydrochloride was made by treating the free base with ethereal hydrochloric acid.
- N-ethyl-3-piperidyl-9-fluorene carboxylate was formed by refluxing 9-fluorene carboxylic acid chloride and N- ethyl-3-hydroxy piperidine in pyridine. A large excess of water was added to the refluxed mixture and the desired product was extracted from the mixture with ether. The mixture was distilled and the distillate was treated with anhydrous ether and hydrochloric acid. The precipitate was crystallized from acetone.
- N-ethyl-3-piperidyl-9-xanthene carboxylate was made by refluxing xanthene-9-carboxylic acid and N-ethyl-3- chloro-piperidine in isopropanol. The residue was dissolved in hydrochloric acid and was extracted with ether.
- the acid layer is made alkaline and again extracted with ether and ether then removed. The residue was heated, dissolved and acidified to form a precipitate. After removal of solvent, the precipitate was crystallized from isopropanol.
- ester includes both the esters in the free state and esters combined with, or with various added acids to form salts.
- N-methyl-3-piperidyl-diphenylacetaite 4.5 g. of N-methyl-3-l1ydroxy-piperidine (0.039 mole) was mixed with 4.0 g. of diphenyl-acctylchloride (0.039 mole) and 50 cc. of dry pyridine which was used as a solvent and was therefore in large molar excess.
- the mixture was refluxed for four hours and 200 ml. of water containing 30 g. of sodium bicarbonate was added.
- the solution was extracted with ether and dried with potassium carbonate.
- the ether was removed by distillation and the desired product was obtained by distilling at 0.06 mm. of mercury.
- the boiling point of the product was 163" C. and 3.0 g. of N-methy1-3-piperidyl-diphenylacetate was obtained.
- the free base is:
- R and R are lower alkyl radicals and X is an inorganic radical such as a halogen, sulfate or other similar radical.
- R be an ethyl and that R be a lower alkyl radical, for the uses to which the present compounds are to be put.
- the methobromide derivative of the above base was obtained by dissolving 15.3 g. (0.046 mole) of the above intermediate in cc. of cold ethyl alcohol to which 15.2 g. (0.16 mole) of methyl bromide was added. The mixture was placed in a closed citrate bottle and allowed to stand for one hundred forty-four hours at room temperature. The mixture was then concentrated at 30 mm. of mercury pressure and a yellow oily product was obtained. All of the volatiles were removed from the product in a vacuum desiccator at 2 mm. of mercury. A white powder was obtained which is hygroscopic and the melting point thereof, which was determined in a sealed tube, was found to be 126-127 C. A yield of 14.3 g.
- N-ethyl-3-piperidyl benzilate, and its related compound N-ethyl-3-chloropiperidine was prepared according to the method of Fuson and Zirkle described in volume 70, J.A.C.S., page 2760. 12.0 g. (0.081 mole) of N-ethyl-3- chloropiperidine was mixed with 18.6 g. (0.081 mole) of benzilic acid and 80 cc. of anhydrous isopropyl alcohol as a solvent. The mixture was refluxed for seventy-two hours. The solution was then filtered and concentrated at 30 mm. of mercury. The concentrate was dissolved in water, acidified with hydrochloric acid and extracted with ether to remove the unreacted benzilic acid.
- N-ethyl-3-piperidyl-benzilate hydrochloride formula is:
- compositions are nontoxic and alleviate or stop smooth muscle spasm regardless of its origin, and that the compounds are free from the undesirable reactions producing pupil dilation, dryness of mouth and other undesirable side effects.
- N-ethyl-3-piperidyl-9-xanthene carboxylate N-ethyl-3-piperidyl-9-xanthene carboxylate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Description
2,995,560 ACETATES OF 3-PIPERIDINOL John H. Biel, Milwaukee, Wis., assignor, by mesne assignments, to Lakeside Laboratories, Inc., Milwaukee, Wis., a corporation of Delaware No Drawing. Filed Sept. 11, 1959, Ser. No. 839,288 9 Claims. (Cl. 260-2943) This invention relates to an ester of cyclic aminoalcohols and particularly to an acetic ester of N-ethyl-3- piperidinol and the salts thereof.
This application is a continuation-in-part of application Serial No. 180,295, filed August 18, 1950, now abandoned, and Serial No. 217,413, filed March 24, 1951, now abandoned.
The reduction or smooth muscle spasm, whether of musculotropic or neurotropic, by atropine, and by various synthetic compounds related in structure to atropine or papaverine, is well known. While many of these compounds will eifectively abolish one or the other type of spasm, they are not capable of relieving both types of muscle spasm. Furthermore, the action of the known compounds is usually accompanied by undesirable side eiieots such as dilatation of the pupil of the eye, dryness of the mouth, large increase in rate of heart beat, hypotension, nausea, and vomiting.
Some esters of N-alkyl-4-piperidinol have been found to be active anti-spasmodics or spasmolytics, but such esters have never been put into use. It is well known that changes in the positions of certain substituents on the piperidine ring may produce profound differences in the physiological activity and effects of such compounds, which differences are not predictable. Thus, N-methyl-4- phenyl-4-propionoXy-piperidine is a potent analgesic, whereas, the corresponding N-methyl-Z-phenyl-Z-propionoxy-pipen'dine has only slight analgesic properties, and beta-4-methyl-piperidine-ethyl benzoate has considerable anesthetic action while the 2- and 3-methyl derivatives have no such action. Hence, it will be seen that shifting a group from the 4-position of the piperidine ring may cause complete loss of activity.
I have found that substituted acetic acid esters of N- ethyl-3-piperidinol are effective as an anti-spasmodic in both musculotropic and neurotropic spasms and have longer duration of action with fewer undesirable side eflects than various other anti-spasmodics now used.
It is, therefore, an object of the present invention to provide a compound for pharmaceutical purposes and having the effect of reducing either involuntary muscle or nervous spasm.
Another object of the invention is to provide a compound having an anti-spasmodic effect in humans, which compound is long lasting in action and which will have only a few undesirable side reactions of minor importance.
A further object of the invention is to provide a series of substituted acetic acid esters of N-ethyl-3-piperidinol having longer activity and side reactions both less in number and of lower intensity than other compounds now in use for reducing spasm of human muscle or nerves.
Generally, the present invention includes the substituted acetic acid esters of N-alkyl-3-piperidinol and the salts thereof and the preparation of such compounds by States atent O the use of simple equipment and procedures. pounds conform to the type formula:
The como-o-cm S Ri where:
R is an alkyl radical R2 is H or OH where: R, and R are lower alkyl radicals and X is an inorganic radical.
N-ethyl-B-piperidyl-diphenylacetate hydrochloride was formed by heating equimolecular amounts of N-ethyl-3- piperidinol and diphenylacetyl chloride in the presence of a solvent for the reactants. The hydrochloride salt was precipitated and is readily purified by recrystallization from a suitable solvent. The free base N-ethyl-S-piperidyl diphenylacetate was obtained as an oily material, by treating thesaid hydrochloride with sodium hydroxide. N- ethyl-3-piperidyl-diphenylacetate-methiodide was formed by treating free N-cthyl-3-piperidyl-diphenylacetate in an ether solution with methyl iodide.
N-methyl-3-piperidyl-diphenylacetate and its hydrochloride salt differ from the preceding compositions by the substitution of a methyl group on the N of the piperidine ring. The base was made by refluxing N- methyl-3-hydroxy-piperidine with diphenylacetyl chloride and pyridine. The refluxed material is neutralized and extracted with ether. The extract was dried and the ether removed, and the base recovered by vacuum distillation. A solution of the base in ethereal hydrochloric acid precipitated the hydrochloride in crystalline form.
N-ethyl-3-piperidyl-phenylcyclohexylacetate and its hydrochloride and other salts differ from the above compounds by reduction of one of the rings of the diphenyl acetic acid moiety to a cyclohexyl ring. Such reduction Was carried out in glacial acetic acid with platinum oxide to give phenylcyclohexylacetic acid. The acid was treated with thionyl chloride to obtain the chloride of the acid which was then reacted with pyridine and N-ethyl-3- piperidinol. The resulting compound was neutralized, extracted with ether and dried. After removing the ether, vacuum distillation gave the desired base. The hydrochloride of the above base was formed by dissolving the base in ether and adding ethereal hydrochloric acid. The methobromide of the above base was formed by dissolvingthe above base in ethyl alcohol and adding methylbromide which is allowed to stand until the reaction is completed. The mixture was then concentrated and the volatiles were removed.
N ethyl 3 piperidyl benzilate hydrochloride differs from the preceding compounds by the addition of a hydroxy group to the diphenylacetic acid moiety. N- ethyl-3-chloro-piperidine, benzilic acid and isopropanol were refluxed together, filtered and concentrated in vacuo. The concentrate was dissolved acidified and the unreacted acid was removed with ether. After neutralizing the aqueous layer of the mixture, the product was extracted with ether and the solution was dried. The ether was removed and the free base was obtained by vacuum distillation. The hydrochloride was made by treating the free base with ethereal hydrochloric acid.
N-ethyl-3-piperidyl-9-fluorene carboxylate was formed by refluxing 9-fluorene carboxylic acid chloride and N- ethyl-3-hydroxy piperidine in pyridine. A large excess of water was added to the refluxed mixture and the desired product was extracted from the mixture with ether. The mixture was distilled and the distillate was treated with anhydrous ether and hydrochloric acid. The precipitate was crystallized from acetone.
N-ethyl-3-piperidyl-9-xanthene carboxylate was made by refluxing xanthene-9-carboxylic acid and N-ethyl-3- chloro-piperidine in isopropanol. The residue was dissolved in hydrochloric acid and was extracted with ether.
The acid layer is made alkaline and again extracted with ether and ether then removed. The residue was heated, dissolved and acidified to form a precipitate. After removal of solvent, the precipitate was crystallized from isopropanol.
As used in the present application, the word ester includes both the esters in the free state and esters combined with, or with various added acids to form salts.
The following examples for illustrative purposes only, show how both the substituted acetic esters of N-ethyl- 3-piperidinol and the salts and substituents thereof may be prepared.
A. Preparation of N-ethyl-S-piperidyl diphenylacetate, and its related compounds To obtain the free base, 34 g. (0.256 mole) of N-ethyl- 3-piperidinol and 20 g. (0.22 mole) of diphenylacetyl chloride were mixed in 80 cc. of isopropanol and the solution was refluxed for two hours. The isopropanol was evaporated in vacuo at 30 mm. pressure, the residue was dissolved in 150 cc. of water and the aqueous solution was extracted several times with ether. The aqueous solution was then neutralized with potassium carbonate and extracted with ether. The ethereal solution was dried over anhydrous potassium carbonate and the ether removed by distillation. The product was then distilled at its boiling point l80181 C. at 0.13 mm. of mercury whereby 14 g. of a clear yellow, viscous liquid was obtained. The nitrogen content for C H NO was calculated as 4.33% and the nitrogen content found was 4.21%. The structural formula for the free base is:
Q II I 0- o S Q N A mixture of 4.5 g. (0.02 mole) of diphenylacetyl chloride and 2.6 g. (0.02 mole) of N-ethyl-3-piperidinol were dissolved in 50 cc. of acetone and refluxed for three hours. The precipitate was filtered out and washed. The precipitate was then dissolved in isopropyl alcohol and recrystallized, a single recrystallization yielding N- ethyl-3-piperidyl-diphenylacetate hydrochloride melting at 173174 C. The yield was 4.2 g. (60% of theoretical). The salt is water soluble and ether insoluble and in water and in alcohol.
has a high melting point. The structural formula for the above salt is:
The chlorine content for C21H2 ClNO (01' C21H25NO21HC1) i r 3 S 2 /N I C2H5 C s The calculated iodine content of C H NIO is 27.3% and the content found was 27.7%. The calculated nitrogen content of the above compound is 3.04% and the content found was 2.98%.
B. Preparation of N-methyl-3-piperidyl-diphenylacetate hydrochloride, and its related compounds 3-hydroxy pyridine was catalytically reduced (by the method of Chen-Heng Kao disclosed in Volume 44 of Chemical Abstracts, page 3993) to 3-hydroxy-piperidine with a boiling point of 67-69 C. at 2 mm. of mercury pressure. 9.0 g. (0.09 mole) of 3-hydroxy-piperidine were mixed with 13.1 g. (0.25 mole) of 88% formic acid and 8.9 g. (0.11 mole) of 37% formaldehyde solution and the mixture was refluxed for twenty-four hours. After addition of 5 ml. of concentrated hydrochloric acid, the mixture was distilled at 30 mm. mercury pressure to remove all volatiles. The residue was dissolved in 20 ml. water and the solution was saturated with potassium hydroxide. The solution was then extracted with ether and the ether was removed by distillation. N-methyl-3- hydroxy-piperidine was obtained by distillation and had a boiling point of 81 C. at 15 mm. of mercury. The yield was 7.0 g. (67% of theoretical). The N content for C H NO was calculated as 11.92% and a content of 11.75% was found.
To obtain N-methyl-3-piperidyl-diphenylacetaite, 4.5 g. of N-methyl-3-l1ydroxy-piperidine (0.039 mole) was mixed with 4.0 g. of diphenyl-acctylchloride (0.039 mole) and 50 cc. of dry pyridine which was used as a solvent and was therefore in large molar excess. The mixture was refluxed for four hours and 200 ml. of water containing 30 g. of sodium bicarbonate was added. The solution was extracted with ether and dried with potassium carbonate. The ether was removed by distillation and the desired product was obtained by distilling at 0.06 mm. of mercury. The boiling point of the product was 163" C. and 3.0 g. of N-methy1-3-piperidyl-diphenylacetate was obtained. The free base is:
The free base was dissolved in ether and ethereal hydrochloric acid solution was added to obtain 2.7 g. of the crystalline hydrochloride. The product was recrystallized from hot acetone and had a melting point of 193 194 C. For C H ClNO a Cl content of 10.29% and an N content of 4.06 were calculated. A Cl content of 10.31% and an N content of 4.13% were found. The structural formula is:
O .HCl
From the above examples it will be apparent that various other onium compounds can be prepared, such compounds being of the character in which the electronic relations provide one or more so-called lone electronic pairs which give a central atom a valence greater than its normal value. Hence, the type compound can be expressed by the structural formula:
where R and R are lower alkyl radicals and X is an inorganic radical such as a halogen, sulfate or other similar radical.
In the abovecompounds, however, it is preferred that R be an ethyl and that R be a lower alkyl radical, for the uses to which the present compounds are to be put.
C. Preparation of N-ethyl-S-piperidyl-phenylcyclohexylacetate, and its related compounds Diphenylacetic acid was reduced (by the method of Smith and Alderman, volume 67 J.A.C.S. page 272) in glacial acetic acid with platinum oxide to obtain phenylcyclohexylacetic acid which was treated with thionyl chloride to obtain phenylcyclohexylacetyl chloride, boiling point of 133-134 C. at 4 mm. mercury pressure. A mixture of 41.2 g. (0.175 mole) of the above acid chloride, 200 ml. anhydrous pyridine (as a solvent having no quantitative relation to the reactants) and 22.6 g. (0.175 mole) of N-ethyl-3-piperidinol was refluxed for six hours. The reaction product was neutralized by addition of 1 liter of 5% of sodium bicarbonate solution. The oily layer was extracted with ether and the extract dried with potassium carbonate. The ether was distilled olf and the residue was distilled at 0.55 mm. of mercury. The product boiled at 172-174 C. and a yield of 45.3 g. (78.9% of theoretical) of N-ethyl-3-piperidyl-phenylcyclohexyl-acetate was obtained. The structural formula for the free base is:
O H 0 S C luHu N jzHfi 10.0 g. of the above intermediate was dissolved in anhydrous ether and treated with an ethereal solution of hydrochloric acid. The oily yellow product was treated with acetone to obtain a white crystalline precipitate melting at 208215 C. The product was recrystallized from isopropyl alcohol and had a melting point of 214- 216 C. A yield of 10.2 g. was obtained which is 93% of theoretical. Based on the formula C H ClNO, the content of Cl was calculated to be 9.72% and the con- 6 tent of N was calculated to be 3.82%. The CI content of 9.50% and N content of 3.55% were found. The structural formula of N-ethyl-3-piperidylphenylcyclohexylacetate hydrochloride is:
O H II I 0-0-0 8 (Hit N (52155 .HCl.
The methobromide derivative of the above base was obtained by dissolving 15.3 g. (0.046 mole) of the above intermediate in cc. of cold ethyl alcohol to which 15.2 g. (0.16 mole) of methyl bromide was added. The mixture was placed in a closed citrate bottle and allowed to stand for one hundred forty-four hours at room temperature. The mixture was then concentrated at 30 mm. of mercury pressure and a yellow oily product was obtained. All of the volatiles were removed from the product in a vacuum desiccator at 2 mm. of mercury. A white powder was obtained which is hygroscopic and the melting point thereof, which was determined in a sealed tube, was found to be 126-127 C. A yield of 14.3 g. (73% of theoretical) was obtained. For the formula C H BrNO Br content of 18.83% and N content of 3.31% were calculated. Br content of 18.49% and N content of 3.27% were found. The structural formula for N-ethyl-3-piperidyl-phenylcyclohexylacetate methobromide is: l
D. Preparation of N-ethyl-3-piperidyl benzilate, and its related compound N-ethyl-3-chloropiperidine was prepared according to the method of Fuson and Zirkle described in volume 70, J.A.C.S., page 2760. 12.0 g. (0.081 mole) of N-ethyl-3- chloropiperidine was mixed with 18.6 g. (0.081 mole) of benzilic acid and 80 cc. of anhydrous isopropyl alcohol as a solvent. The mixture was refluxed for seventy-two hours. The solution was then filtered and concentrated at 30 mm. of mercury. The concentrate was dissolved in water, acidified with hydrochloric acid and extracted with ether to remove the unreacted benzilic acid.
The aqueous layer was neutralized with sodium bicarbonate and the product was extracted with ether. The etheral solution of the product was dried with potassium carbonate, the ether was removed by distillation and the residue was distilled at 0.12-0.18 mm. of mercury, the boiling point being 194-198" C. A yield of 16.5 g. 60% of theoretical) of N-ethyl-B-piperidyl-benzilate was obtained. The structural formula is:
6.4 g. of the above free base was dissolved in acetone and ethereal hydrochloric acid added. 6.2 g. of white crystals were obtained, the crystals having a melting point of 186-187 C. The yield was 86% of theoretical. For the formula C H ClNO a chlorine content of 9.45%
was calculated and the content found was 9.29%. A nitrogen content of 3.72% was calculated and the nitrogen content found was 3.62%. The structural formula for N-ethyl-3-piperidyl-benzilate hydrochloride formula is:
It will be apparent from the various examples given above that other piperidyl esters may be made with different acid moieties.
E. Preparation of N-ethyl-3-piperidyl-9- uorenecarboxylate A mixture of 14.0 g. (0.064 mole) of 9-fluorenecarboxylic acid chloride and 9.0 g. (0.074 mole) of N-ethyl-3-hydroxy piperidine was dissolved in 60 cc. pyridine and was refluxed for one hour. The product was cooled and mixed with 400 cc. of water. The oily yellow precipitate was extracted with ether and the extract was dried over potassium carbonate. The extract was distilled at 0.3 mm. of mercury at 205-215" C. to obtain 2.0 g. of distillate.
The distillate was dissolved in anhydrous ether and acidified with ethereal hydrochloric acid. A gummy precipitate formed from which the ether was decanted. The precipitate was crystallized from acetone to yield 0.1 g. of the desired product (0.4% of theoretical), melting at 226227 C. For the formula C H C1NO a Cl content of 9.94% was calculated and Cl content of 9.97% was found. The structural formula of the above base is:
F. Preparation of N-ethyl-3-piperidyl-9-xanthene carboxylate A mixture of 11.0 g. (0.049 mole) of xanthene-9- carboxylic acid and 7.2 g. (0.049 mole) of N-ethyl-3- chloropiperidine was dissolved in 50 cc. of dry isopropyl alcohol and refluxed for seventy-two hours. The mixture was then concentrated at 30 mm. pressure.
The residue was partially dissolved in dilute aqueous hydrochloric acid and extracted twice with ether. The aqueous layer was made alkaline with sodium hydroxide solution and extracted with ether. The extract was dried over potassium carbonate and the ether was removed by distillation. The residue was first heated over a bath water under a vacuum of 2 mm. mercury to remove low boiling point materials and was then dissolved in anhydrous ether and acidified with ethereal hydrochloric acid. A gummy precipitate formed from which the ether was decanted. The precipitate was crystallized in hot isopropyl alcohol to yield 4.1 g. (22% of theoretical) of the desired product. The product had a melting point of 226227 C. For the formula C H ClNO a Cl content 9.51% was calculated and Cl content of 9.34% found. An N content 3.75% was calculated and N content 3.74% found. The structural formula of the above free base is:
@Oig/ G. Preparation of N-ethyl-3-piperidyl phenylcyclopentylacetate and hydrochloride thereof 0 oon o O 2 1 .1101
To 114 g. (0.88 mole) of N-ethyl-3-hydroxypiperidine in 500 cc. of anhydrous benzene was added 196.6 g. (0.88 mole) of phenylcyclopentylacetyl chloride in 500 cc. of benzene in the presence of 107 g. (1.06 moles) of triethylamine. The reaction mixture was stirred at 65-75 C. for 4 hours and the triethylamine hydrochloride removed by filtration. The filtrate was distilled and the basic ester collected at 154-17-8 C. (0.04 mm), yield 220 g. (79% The hydrochloride salt was formed in acetone by the addition of ethereal hydrochloric acid. The crude salt was recrystallized repeatedly from acetone, M.P. 181- 183 C.
Analysis.-Calcd. for C H ClNO 01, 10.10; N, 3.98. Found: Cl, 10.13; N, 4.12.
It has been found that the present compositions are nontoxic and alleviate or stop smooth muscle spasm regardless of its origin, and that the compounds are free from the undesirable reactions producing pupil dilation, dryness of mouth and other undesirable side effects.
It is well known that the anti-spasmodic activity of compounds such as the salts disclosed herein, is due to the ester portion of the molecule and not to the acid used to form the salts. Hence, it will be understood that various salts other than those herein disclosed, may be readily made. Such other additional salts include particularly the hydrobromide, maleate, succinate, tartrate, benzoate and phosphate, and are readily prepared from the free base and the corresponding acid in solvents such as acetone, benzene, ether type compounds, ethanol, isopropanol, and other alcohols.
Various changes and modifications of the invention can be made and, to the extent that such variations incorporate the spirit of this invention, they are intended to be included within the scope of the appended claims.
What is claimed is:
. N-lower alkyl-3-piperidyl-phenyl-cyclohexyl acetate. 2. N-ethyl-3-piperidyl-phenyl-cyclohexyl acetate.
3. N-lower alkyl-3-piperidyl-9-fiuorene carboxylate.
4. N-ethyl-3-piperidyl-9-fiuorene carboxylate.
g. N-lower alkyl-3-piperidyl-9-xanthene carboxylate. 7
. N-ethyl-3-piperidyl-9-xanthene carboxylate.
. N-lower acewherein R is lower alkyl, R is a member of the group 9 consisting of phenyl, cyclopentyl, cyclohexyl and Z-thienyl, R is a member of the group consisting of cyclopentyl, cyclohexyl, Z-thienyl and groups in which represents a member of the group consisting of fluorenyl and xanthenyl, and nontoxic pharmaceutically acceptable acid addition salts and nontoxic pharmaceutically acceptable lower alkyl halide quaternary ammonium salts thereof.
References Cited in the file of this patent UNITED STATES PATENTS 2,265,184 Miescher et a1. Dec. 9, 1941 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 2,995,560 August 8, 1961 John H. Biel It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
Column 6, line 55, for "etheral" read ethereal lines 64 to 68, the formula should appear as shown below instead of as in the patent:
Signed and sealed this 2nd day of January 1962.
(SEAL) Attest:
DAVID L, LADD ERNEST w, SWIDER Attesting Officer Commissioner of Hatents
Claims (1)
- 9. A MEMBER OF THE GROUP CONSISTING OF COMPOUNDS OF THE FORMULA
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US839288A US2995560A (en) | 1959-09-11 | 1959-09-11 | Acetates of 3-piperidinol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US839288A US2995560A (en) | 1959-09-11 | 1959-09-11 | Acetates of 3-piperidinol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2995560A true US2995560A (en) | 1961-08-08 |
Family
ID=25279334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US839288A Expired - Lifetime US2995560A (en) | 1959-09-11 | 1959-09-11 | Acetates of 3-piperidinol |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2995560A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3138614A (en) * | 1961-12-18 | 1964-06-23 | Lilly Co Eli | Salts of 1, 1-dimethyl-3-pyrrolidyl phenyl-2-thienylglycolate |
| US6761292B1 (en) * | 2002-08-13 | 2004-07-13 | Elyse L. Newman | Device adapted for use in donning a ski boot and method of using said device |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB448181A (en) * | 1934-07-12 | 1936-05-25 | Chem Ind Basel | Manufacture of basic esters of polyarylacetic acids |
| GB483258A (en) * | 1936-06-08 | 1938-04-14 | Arthur George Bloxam | Manufacture of basic esters of polyarylacetic acids |
| US2265184A (en) * | 1938-08-05 | 1941-12-09 | Ciba Pharm Prod Inc | Basic esters and process of preparing same |
| US2387879A (en) * | 1940-04-20 | 1945-10-30 | Searle & Co | Piperidinol esters as antispasmodic agents |
| US2477937A (en) * | 1945-01-13 | 1949-08-02 | Rhone Poulenc Sa | N-hydrocarbon 3-piperidinols |
| US2533002A (en) * | 1949-10-29 | 1950-12-05 | Sterling Drug Inc | 1-methyl-3-piperidylmethyl phenyl-(2-thienyl) acetate, its salts and production thereof |
| US2607777A (en) * | 1947-04-10 | 1952-08-19 | Searle & Co | N-alkyl piperidyl alkyl esters of diphenyl acetic acid and 9-fluorenyl carboxylic acid |
| US2648667A (en) * | 1951-04-18 | 1953-08-11 | Hoffmann La Roche | Esters of 1-azabicycloalkanols |
| US2659725A (en) * | 1950-06-21 | 1953-11-17 | Searle & Co | Quaternary ammonium salts of heterocyclylalkanol esters of xanthene-9-carboxylic acid |
| US2788364A (en) * | 1953-01-15 | 1957-04-09 | Searle & Co | Quaternary ammonium salts of dialkylaminoalkyl fluorene-9-carboxylates and the preparation thereof |
| US2918408A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
| US2918407A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodics specific for upper gastrointestinal pain and spasm |
| US2918406A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodics specific for peptic ulcer |
-
1959
- 1959-09-11 US US839288A patent/US2995560A/en not_active Expired - Lifetime
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB448181A (en) * | 1934-07-12 | 1936-05-25 | Chem Ind Basel | Manufacture of basic esters of polyarylacetic acids |
| GB483258A (en) * | 1936-06-08 | 1938-04-14 | Arthur George Bloxam | Manufacture of basic esters of polyarylacetic acids |
| US2265184A (en) * | 1938-08-05 | 1941-12-09 | Ciba Pharm Prod Inc | Basic esters and process of preparing same |
| US2387879A (en) * | 1940-04-20 | 1945-10-30 | Searle & Co | Piperidinol esters as antispasmodic agents |
| US2477937A (en) * | 1945-01-13 | 1949-08-02 | Rhone Poulenc Sa | N-hydrocarbon 3-piperidinols |
| US2607777A (en) * | 1947-04-10 | 1952-08-19 | Searle & Co | N-alkyl piperidyl alkyl esters of diphenyl acetic acid and 9-fluorenyl carboxylic acid |
| US2533002A (en) * | 1949-10-29 | 1950-12-05 | Sterling Drug Inc | 1-methyl-3-piperidylmethyl phenyl-(2-thienyl) acetate, its salts and production thereof |
| US2659725A (en) * | 1950-06-21 | 1953-11-17 | Searle & Co | Quaternary ammonium salts of heterocyclylalkanol esters of xanthene-9-carboxylic acid |
| US2648667A (en) * | 1951-04-18 | 1953-08-11 | Hoffmann La Roche | Esters of 1-azabicycloalkanols |
| US2788364A (en) * | 1953-01-15 | 1957-04-09 | Searle & Co | Quaternary ammonium salts of dialkylaminoalkyl fluorene-9-carboxylates and the preparation thereof |
| US2918408A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
| US2918407A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodics specific for upper gastrointestinal pain and spasm |
| US2918406A (en) * | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodics specific for peptic ulcer |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3138614A (en) * | 1961-12-18 | 1964-06-23 | Lilly Co Eli | Salts of 1, 1-dimethyl-3-pyrrolidyl phenyl-2-thienylglycolate |
| US6761292B1 (en) * | 2002-08-13 | 2004-07-13 | Elyse L. Newman | Device adapted for use in donning a ski boot and method of using said device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO153082B (en) | APPARATUS FOR STAPPING A WRINKED RODFORM SHEET | |
| DE1216866B (en) | Process for the preparation of carboxylic acid esters of 4-aminobutyn- (2) -ols- (1) and their therapeutically acceptable salts | |
| US3116291A (en) | 9-(propene-3-ylidene-1), and 9-[3'-(nu-hydrox-yalkylpiperazino-nu)-propylidene], xanthenes and thiaxanthenes, and processes for their preparation | |
| US2846437A (en) | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof | |
| NO803453L (en) | PROCEDURE FOR THE PREPARATION OF PIPERIDYLBENZIMIDAZOLONE DERIVATIVES | |
| US4021564A (en) | Neuroleptic piperidine compounds | |
| US2688021A (en) | Bicycloheptene and bicyclooctene-2-carboxylic acid esters | |
| US3557127A (en) | Substituted cyclohexenes,derivatives thereof and processes for obtaining same | |
| US3479346A (en) | N-acyl-n- (and n,n-bis-) ((1-piperidyl)-lower-alkyl)amines | |
| US2606205A (en) | Dihalogen benzoic acid esters of amino alcohols | |
| US2995560A (en) | Acetates of 3-piperidinol | |
| US3360526A (en) | Heterocyclicamino methylene ethers of benzylphenols | |
| US3077470A (en) | 3-[4-hydroxy-3-(aminomethyl)-phenyl]-4-(4-oxyphenyl)-alkanes and alkenes | |
| US3077472A (en) | 3-[4-(aminoalkoxy)-phenyl]-4-(4-oxyphenyl)-alkanes and alkenes | |
| US2918407A (en) | Anti-spasmodics specific for upper gastrointestinal pain and spasm | |
| US4339576A (en) | Anti-asthmatic, anti-allergic, anti-cholinergic, bronchodilator and anti-inflammatory 1-[(benzoylphenyl)-lower-alkyl]piperidines and analogs thereof | |
| US2884426A (en) | Basic esters of mandelic acid and a process of making same | |
| EP0506903A1 (en) | 4-acetoxy-piperidine derivatives, process for their preparation and use as a muscarinic m3-receptor antagonist | |
| US4474783A (en) | Cyclopropylmethyl piperazines, the process for preparing the same and their use in therapeutics | |
| EP0052311A1 (en) | 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof | |
| US3184467A (en) | Gkanatanol-(j beta)-estees | |
| US2485662A (en) | Alpha-(aminoalkyl)-stilbenes | |
| NO128798B (en) | ||
| CH460773A (en) | Process for the preparation of substituted 3- (3-hydroxyphenyl) -1-phenacyl-piperidines | |
| US3093651A (en) | Nu-alkyl-2-(2-[9-carbazolyl-ethyl])-piperidines |